SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hanan Mohamed El Kahky, Heba Mahmoud Diab, Dalia Gamal Aly, Nehal Magdi Farag, Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis, Dermatology Research and Practice, 2013, 2013, 1

    CrossRef

  2. 2
    Maura Krähembühl Wanderley Bittencourt, José Paulo Cabral de Vasconcellos, Matheus Domingues Bittencourt, Rodolfo Malagó, Marianna Bacellar, Evaluation of the Efficacy and Safety of Botulinum Toxin Type A to Induce Temporary Ptosis in Dogs, Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 4, 431

    CrossRef

  3. 3
    Reiner Benecke, Clinical Relevance of Botulinum Toxin Immunogenicity, BioDrugs, 2012, 26, 2, e1

    CrossRef

  4. 4
    Anna Rita Bentivoglio, Tàmara Ialongo, Francesco Bove, Francesca De Nigris, Alfonso Fasano, Retrospective evaluation of the dose equivalence of Botox® and Dysport® in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story, Neurological Sciences, 2012, 33, 2, 261

    CrossRef

  5. 5
    Amit Batla, Maria Stamelou, Kailash P. Bhatia, Treatment of Focal Dystonia, Current Treatment Options in Neurology, 2012, 14, 3, 213

    CrossRef

  6. 6
    David Charles, Chandler Gill, Handbook of Dystonia, 2012,

    CrossRef

  7. 7
    Mark Stacy, Patrick Hickey, Handbook of Dystonia, 2012,

    CrossRef

  8. 8
    Arianna Guidubaldi, Alfonso Fasano, Tamara Ialongo, Carla Piano, Maurizio Pompili, Roberta Mascianà, Luisa Siciliani, Mario Sabatelli, Anna Rita Bentivoglio, Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease, Movement Disorders, 2011, 26, 2
  9. 9
    Christoph Kamm, Reiner Benecke, Botulinum toxin therapy for cervical dystonia: review of the clinical evidence and ongoing studies, Clinical Investigation, 2011, 1, 6, 891

    CrossRef

  10. 10
    Laura G. Stansell, Ariana L. Smith, William I. Jaffe, Treatment of Neurogenic Voiding Dysfunction: An Update, Current Bladder Dysfunction Reports, 2011, 6, 1, 37

    CrossRef

  11. 11
    K. Roger Aoki, Botulinum Toxins in Clinical Aesthetic Practice, 2011,

    CrossRef

  12. 12
    Marian L. Evatt, Alan Freeman, Stewart Factor, Hyperkinetic Movement Disorders, 2011,

    CrossRef

  13. 13
    Syrus Karsai, Christian Raulin, Botox and Dysport: Is there a dose conversion ratio in dermatology and aesthetic medicine?, Journal of the American Academy of Dermatology, 2010, 62, 2, 346

    CrossRef

  14. 14
    Fernanda Martins Maia, Aline Kozoroski Kanashiro, Hsin Fen Chien, Lílian Regina Gonçalves, Egberto Reis Barbosa, Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients, Parkinsonism & Related Disorders, 2010, 16, 1, 8

    CrossRef

  15. 15
    Jürgen Frevert, Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®, Drugs in R & D, 2010, 10, 2, 67

    CrossRef

  16. 16
    Jürgen Frevert, Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®, Drugs in R&D, 2010, 10, 2, 67

    CrossRef

  17. 17
    Jarosław Sławek, Halina Car, Marcin Bonikowski, Andrzej Bogucki, Dariusz Koziorowski, Anna Potulska-Chromik, Monika Rudzińska, Czy wszystkie preparaty toksyny botulinowej typu A są takie same? Porównanie trzech preparatów toksyny botulinowej typu A w zarejestrowanych wskazaniach w neurologii, Neurologia i Neurochirurgia Polska, 2010, 44, 1, 43

    CrossRef

  18. 18
    Katja Kollewe, Bahram Mohammadi, Reinhard Dengler, Dirk Dressler, Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®, Journal of Neural Transmission, 2010, 117, 6, 759

    CrossRef

  19. 19
    Gavin De Aguiar, Reply, Plastic and Reconstructive Surgery, 2010, 125, 2, 754

    CrossRef

  20. 20
    Elena Moro, Marie Vidailhet, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  21. 21
    B. Mohammadi, N. Buhr, H. Bigalke, K. Krampfl, R. Dengler, K. Kollewe, A long-term follow-up of botulinum toxin A in cervical dystonia, Neurological Research, 2009, 31, 5, 463

    CrossRef

  22. 22
    Jae Ho Shin, Chan Jeon, Kyung In Woo, Yoon Duck Kim, Clinical Comparability of Dysport and Botox in Essential Blepharospasm, Journal of the Korean Ophthalmological Society, 2009, 50, 3, 331

    CrossRef

  23. 23
    SYRUS KARSAI, CHRISTIAN RAULIN, Current Evidence on the Unit Equivalence of Different Botulinum Neurotoxin A Formulations and Recommendations for Clinical Practice in Dermatology, Dermatologic Surgery, 2009, 35, 1, 1

    CrossRef

  24. 24
    Kai Wohlfarth, Thomas Sycha, Danièle Ranoux, Hans Naver, David Caird, Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?, Current Medical Research and Opinion, 2009, 25, 7, 1573

    CrossRef

  25. 25
    Bahram Mohammadi, Katja Kollewe, Maresa Wegener, Hans Bigalke, Reinhard Dengler, Experience with long-term treatment with albumin-supplemented botulinum toxin type A, Journal of Neural Transmission, 2009, 116, 4, 437

    CrossRef

  26. 26
    C. Beylot, Les différentes toxines botuliques et leurs spécificités, Annales de Dermatologie et de Vénéréologie, 2009, 136, S77

    CrossRef

  27. 27
    M. T. Pérez-Saldaña, E. K. Tan, J. A. Burguera, Long-term treatment outcome with different formulations of botulinum toxin, European Journal of Neurology, 2009, 16, 3
  28. 28
    Gottfried Kranz, Dietrich Haubenberger, Bernhard Voller, Martin Posch, Peter Schnider, Eduard Auff, Thomas Sycha, Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study, Movement Disorders, 2009, 24, 2
  29. 29
    K. Wohlfarth, I. Schwandt, F. Wegner, T. Jürgens, G. Gelbrich, A. Wagner, U. Bogdahn, W. Schulte-Mattler, Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers, Journal of Neurology, 2008, 255, 12, 1932

    CrossRef

  30. 30
    Allison Brashear, Clinical Comparisons of Botulinum Neurotoxin Formulations, The Neurologist, 2008, 14, 5, 289

    CrossRef

  31. 31
    Arnold W. Klein, Alastair Carruthers, Steven Fagien, Nicholas J. Lowe, Comparisons among Botulinum Toxins: An Evidence-Based Review, Plastic and Reconstructive Surgery, 2008, 121, 6, 413e

    CrossRef

  32. 32
    Daniel Truong, Cynthia Comella, Hubert H. Fernandez, William G. Ondo, Efficacy and safety of purified botulinum toxin type A (Dysport®) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial, Parkinsonism & Related Disorders, 2008, 14, 5, 407

    CrossRef

  33. 33
    C. L. Comella, The treatment of cervical dystonia with botulinum toxins, Journal of Neural Transmission, 2008, 115, 4, 579

    CrossRef

  34. 34
    Stanislaw Ochudlo, Piotr Bryniarski, Grzegorz Opala, Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm, Parkinsonism & Related Disorders, 2007, 13, 8, 505

    CrossRef

  35. 35
    R. Wenzel, D. Jones, J. A. Borrego, Comparing two botulinum toxin type A formulations using manufacturers’ product summaries, Journal of Clinical Pharmacy and Therapeutics, 2007, 32, 4
  36. 36
    Mary Ann Chapman, Rich Barron, David C. Tanis, Chandler E. Gill, P. David Charles, Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical Dystonia, Clinical Therapeutics, 2007, 29, 7, 1325

    CrossRef

  37. 37
    Joaquim J Ferreira, João Costa, Miguel Coelho, Cristina Sampaio, The management of cervical dystonia, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 129

    CrossRef

  38. 38
    Christopher P. Smith, George T. Somogyi, Update on use of botulinum toxin to treat overactive bladder, Current Bladder Dysfunction Reports, 2007, 2, 2, 65

    CrossRef

  39. 39
    Keith A. Foster, Hans Bigalke, K. Roger Aoki, Botulinum neurotoxin — from laboratory to bedside, Neurotoxicity Research, 2006, 9, 2-3, 133

    CrossRef

  40. 40
    Joseph Jankovic, Botulinum toxin therapy for cervical dystonia, Neurotoxicity Research, 2006, 9, 2-3, 145

    CrossRef

  41. 41
    Robin S. Kingswell, David Caird, Comments and corrections on the REAL DOSE study, Movement Disorders, 2006, 21, 4
  42. 42
    Pierre Denys, Jacques Corcos, Karel Everaert, Emmanuel Chartier-Kastler, Clare Fowler, Vinay Kalsi, Victor Nitti, Heinrich Schulte-Baukloh, Brigitte Schurch, Improving the global management of the neurogenic bladder patient: part II.Future treatment strategies, Current Medical Research and Opinion, 2006, 22, 5, 851

    CrossRef

  43. 43
    Raf Magar, Reply: Comments and corrections on the REAL DOSE study, Movement Disorders, 2006, 21, 4
  44. 44
    K. R. Aoki, D. Ranoux, J. Wissel, Using translational medicine to understand clinical differences between botulinum toxin formulations, European Journal of Neurology, 2006, 13,
  45. 45
    Mark A. Stacy, Handbook of Dystonia, 2006,

    CrossRef